Equities analysts predict that Alaunos Therapeutics, Inc. (NASDAQ:TCRT – Get Rating) will post earnings per share of ($0.09) for the current quarter, according to Zacks Investment Research. Zero analysts have issued estimates for Alaunos Therapeutics’ earnings, with the highest EPS estimate coming in at ($0.05) and the lowest estimate coming in at ($0.13). Alaunos Therapeutics reported earnings of ($0.11) per share during the same quarter last year, which suggests a positive year-over-year growth rate of 18.2%. The firm is scheduled to issue its next earnings results on Monday, January 1st.
On average, analysts expect that Alaunos Therapeutics will report full year earnings of ($0.32) per share for the current financial year, with EPS estimates ranging from ($0.40) to ($0.22). For the next fiscal year, analysts forecast that the company will post earnings of ($0.33) per share, with EPS estimates ranging from ($0.37) to ($0.30). Zacks Investment Research’s earnings per share averages are a mean average based on a survey of sell-side analysts that follow Alaunos Therapeutics.
Alaunos Therapeutics (NASDAQ:TCRT – Get Rating) last posted its quarterly earnings data on Monday, May 16th. The company reported ($0.05) earnings per share for the quarter, hitting the consensus estimate of ($0.05).
Shares of TCRT stock traded up $0.01 on Thursday, hitting $0.51. 27,009 shares of the stock were exchanged, compared to its average volume of 2,864,661. The company has a debt-to-equity ratio of 0.28, a current ratio of 4.91 and a quick ratio of 4.91. The stock has a market cap of $109.38 million, a price-to-earnings ratio of -1.32 and a beta of 1.58. The business has a 50-day moving average of $0.58. Alaunos Therapeutics has a fifty-two week low of $0.41 and a fifty-two week high of $3.73.
About Alaunos Therapeutics (Get Rating)
Alaunos Therapeutics, Inc, a clinical-stage oncology-focused cell therapy company, develops adoptive TCR engineered T-cell therapies. It develops TCR Library, which is in Phase I/II clinical trial for ten TCRs reactive to mutated KRAS, TP53, and EGFR from its TCR library for the treatment of non-small cell lung, colorectal, endometrial, pancreatic, ovarian, and bile duct cancers; hunTR, a human neoantigen T-cell receptor platform; and mbIL-15 to treat solid tumors.
- Get a free copy of the StockNews.com research report on Alaunos Therapeutics (TCRT)
- The Institutions Are Capping Gains In Take-Two Interactive
- Walmart’s “Everyday Low Prices” Gets Burned By Inflation
- VMWare Inc: Strong Revenues and Excellent Potential
- Beware The Rebound In Home Depot
- Time to Ride These 3 Mid Cap Momentum Plays
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Alaunos Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alaunos Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.